Clinical trial · Interventional
Effect of Vitamin C in Autologous Stem Cell Transplantations
Randomized Controlled Trial on the Effect of Vitamin C Supplementation in Autologous Stem Cell Transplantations
NCT03964688CI-TRIAL-00057920VICASTcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the study the investigators will randomize patients that receive an autologous stem cell transplantation for myeloma or lymphoma for treatment with vitamin C or placebo during 6 weeks. Primary endpoint will be immune recovery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Myeloma Multiple | Multiple Myeloma | PROBABILISTIC | 0.70 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebos | Drug | — | UNRESOLVED |
| Vitamin C | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Vitamin C
- description
- vitamin C intravenous during hospitalization, followed with vitamin C oral
- interventionNames
- Drug: Vitamin C
- type
- EXPERIMENTAL
- label
- Placebo
- description
- placebo intravenous during hospitalization, followed with placebo oral
- interventionNames
- Drug: Placebos
Primary outcomes (1)
- measure
- immune recovery
- timeFrame
- day 14-28
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years or older * written informed consent * diagnosis of malignant lymphoma or multiple myeloma * require chemotherapy plus autologous stem cell transplantation as standard of care for the disease at that stage * central venous catheter in place or planned Exclusion Criteria: * inability to understand the nature and extent of the trial and the procedures required * history of kidney stones * kidney failure requiring dialysis or eGFR \<30 mL/min. (CDK-EPI formula) * history of G6PD deficiency * life expectancy \< 1 month * use of immunosuppressive medication other than chemotherapy and corticosteroids
References
Publications (0)
Data not yet available
No reference posted for this study.